Skip to content
OpenCapital
Collapse sidebar
Watchlist
Screener
Filings
Earnings
Charts
Collapse sidebar
Screener
Stocks
COA
Hemab Therapeutics Holdings, Inc.
Business Segments
Products & Services
Research And Development Expense Excluding Acquired In Process Cost
COA
Research And Development Expense Excluding Acquired In Process Cost
Hemab Therapeutics Holdings, Inc.
·
Products & Services
·
1 segment
·
Rolls up to
R&D
Breakdown
Segments
Sutacimig
View metric
Watchlist
Screener
Filings
Earnings
Charts
Quarterly
Annual
TTM
Segment
Q1 '26
Q2 '26
Sutacimig
$5.8M
$5.37M
Total
$19.46M
$20.34M